Kornimate/medical-research-clean huggingface dataset:
maitland mobilization versus mulligan mobilization in sub-acute and chronic non-specific neck pain

Conditions: Nonspecific Neck Pain

Summary: this study investigate the short term effect of maitland in comparison to mulligan mobilization with sub-acute and chronic non specific neck pain to improve neck pain, pain pressure threshold, rang of motion, joint position sense, disability, and to evaluate the interaction with psychological factors. study design: experimental study

44 patients with sub-acute or chronic neck pain will be randomized into maitland group: 22 patients receive central postro anterior or unilateral postero anterior. mulligan group: 22 patients receive sustain natural apophyseal glides. the treatment will be 2 times /week for three weeks. measurement will be taken pre intervention and after three weeks for neck pain, pain pressure threshold, range of motion, joint position sense, and disability using a numeric pain rating scale, pain pressure threshold test, cervical range of motion device, and neck disability index, depression, anxiety, fear avoidance believe and pain catestrophizing respectively.

Eligibility criteria:
inclusion criteria: * • patients aged between 20 to 50 years. * neck pain more than one week without radicular symptoms. * pain on posterior neck from superior nuchal line to first thoracic vertebra. exclusion criteria: * • patient contraindicate to mobilization (pregnancy, whiplash injury, tumor, fracture, metabolic diseases, rheumatoid arthritis, osteoporosis and resting blood pressure higher than 140/90 mmhg). * cervical radiculopathy. * fibromyalgia pain syndrome. * previous neck surgery. * neck pain associate with vertigo caused by vertebrobasilar insufficiency or chronic headache. * patient received physical therapy treatment in the previous three months. * psychiatric disorders. * vestibular system deficits.

Keywords: neck pain,
comparative analysis of rirs scoring system and resorlu unsal stone score (russ) for predicting stone-free rate after retrograde intrarenal surgery

Conditions: Renal Stones

Summary: several studies have investigated the use of scoring systems for predicting stone-free rates after rirs. previous research has evaluated the rirs scoring system, russ, and other similar systems in different patient populations. this study was conducted to compare rirs scoring system and resorlu unsal stone score (russ) for predicting stone free rate.


Eligibility criteria:
inclusion criteria: * patients more than 18 years of age undergoing rirs for renal stone * providing informed written consent exclusion criteria: * previous renal and ureteric surgeries * coexisting bladder, ureteral stone
oral androgens in man-3 (oral t-3) pharmacokinetics of oral testosterone

Conditions: Contraception; Hypogonadism

Summary: the purpose of this study is to test the how the body absorbs and processes new forms of oral testosterone. information gained during the study may help develop better forms of testosterone therapy in the future. we will be administering three drugs. dutasteride is fda approved to treat prostate enlargement. lupron is approved for treatment of prostate cancer. testosterone is approved for treatment of testicular insufficiency. they are being used in this study for "off-label" research purposes. this study will allow us to find out the effect of food on two formulations of testosterone taken by mouth, and the relative effect of food on testosterone absorption. information from this study may be useful in treatment of men with low testosterone levels and the development of a male hormonal contraceptive.

the drug lupron, will temporarily turn off the body's production of testosterone after two weeks. at that point, we will administer testosterone by mouth on six days in the next two weeks to see how much is absorbed and present in the bloodstream after administration. the day lupron is given, and for 24 days after that, subjects will take the second medication, dutasteride, which alters testosterone breakdown in the body. fifteen days after the lupron shot, subjects will take the first formulation of testosterone by mouth and undergo blood draws to see how much of this testosterone makes it into the blood stream and how long it lasts. the next day(day 2) subjects will take a larger dose of testosterone and undergo blood draws. on study day 3, subjects will again take the larger dose of testosterone, this time with a meal and undergo blood draws. during the 2nd week of the study, subjects will repeat the testosterone doses, with a 2nd formulation of testosterone. the first two doses of testosterone each week will be taken on an empty stomach, while the third will be taken with breakfast. please note that six study days: 1,2,3,8,9 and 10 will require repeated blood draws over a 12 hour period.

Eligibility criteria:
inclusion criteria: * male 18-50 yrs old * in good general health based on normal screening evaluation (consisting of medical history, physical exam, normal serum chemistry, hematology, and baseline hormone levels) exclusion criteria: * poor general health, with abnormal blood results at screening * a known history of alcohol or drug abuse * participation in a long-term male contraceptive study within three months of screening

Keywords: male contraception testosterone hypogonadism
to evaluate luts and complications between indwelling catheter and temporary prostatic stent in patients undergoing minimally invasive procedures for the treatment of localized prostate cancer or benign prostatic hyperplasia (hermes)

Conditions: Lower Urinary Tract Symptoms; Prostatic Hyperplasia; Prostatic Cancer; Urinary Retention

Summary: the goal of this single-centre prospective randomized clinical trial is to compare the post-operative use of temporary prostatic stent (group 1) vs indwelling catheter (group 2) in patients undergoing cryotherapy for targeted therapy of localized prostate cancer, transurethral water vapor energy ablation (rezum) or transperineal laser ablation of the prostate with echolaser™ system for the treatment of benign prostatic hyperplasia (bph) the main questions are: * difference in quality of life, lower urinary tract symptoms (scored with ipss, international prostate symptom score), urinary continence symptoms (scored with international consultation on incontinence questionnaire-urinary incontinence short form, iciq-ui-sf) and patient satisfaction between indwelling catheter and temporary prostatic stent (exime®) score with a non-validated questionnaire (stent/catheter-related urinary symptoms questionnaire) * difference in side effects and complications between indwelling catheter and temporary prostatic stent (exime®) a total 120 of patients will be enrolled (group 1: 60; group 2: 60) with a 1:1 randomization ratio. the follow-up duration will be 6 months.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent prior to enrollment (if applicable). * subjects must meet all inclusion criteria to be eligible for study enrollment. * men between 18 and 85 years old. * undergo focal therapy for prostate cancer, water vapour energy ablation rezum® or echolaser®. * willing to be seen by the investigator and answer questions and fill out questionnaires up to a month after surgery. exclusion criteria: * urethral stricture \<22f. * gross haematuria * prostate volume \> 80cc * prostate craniocaudal length \> 6cm * patients with long-term urinary catheters or other urinary drainage systems * lack of commitment on the part of the patient to attend the follow-up as required.

Keywords: temporary prostatic stent indwelling catheter cryotherapy prostate cancer benign prostatic hyperplasia rezum echolaser
rezum for 30-80ml patients with moderate-severe luts to study surgical principles for median lobe enlargement

Conditions: Prostatic Hyperplasia of the Medial Lobe

Summary: this study was created to determine the safety and efficacy of treating prostatic hyperplasia with or without prominent median lobe enlargement with the rezum technique. the systematic implementation of decisions for the location, vapor time, and the number of injections contributes to the rezum procedure configuration for the median lobe treatment being safer and standardizer.


Eligibility criteria:
inclusion criteria: * patients aged 50 to 85 years who have been diagnosed with benign prostatic hyperplasia at seoul national university hospital and are scheduled to undergo endoscopic surgery. * benign prostatic hyperplasia ≥ 30 and \< 80 ml * patients who have given written informed consent to participate in the study according to their age * a urinary symptom score (international prostatesymptom score \[ipss\] moderated (8-19 points) to severe (20-35 points) * measured postvoiding residual (pvr) \<250 ml exclusion criteria: * history of prostate or bladder cancer, neurogenic bladder, bladder calculus, or clinically significant bladder diverticulum * active infection, treatment for chronic prostatitis * diagnosis of urethral stricture, meatal stenosis or bladder neck contracture, damaged external urinary sphincter, stress urinary incontinence, post-void residual \>300 ml or urinary retention, or prior prostate surgery * men taking anticoagulants or on bladder anticholinergics or with severe cardiovascular disease * psa greater than 4.0 ng/ml (unless prostate cancer was ruled out by biopsy) * allergy to device materials, immune suppressants or corticosteroids use, and serious medical or mental illness.

Keywords: median lobe enlargement lower urinary tract symptoms international prostate symptoms score
comparison of acetaminophen with codeine and ibuprofen for children with injuries

Conditions: Pain

Summary: we compared the pain relief of acetaminophen with codeine versus ibuprofen for children ages 5-18 years who came to the pediatric emergency department with injuries to their arms or legs.

we conducted a randomized, double-blinded equivalence trial. pediatric emergency department patients 5-18 years of age with acute extremity pain received acetaminophen-codeine (1 mg/kg as codeine) or ibuprofen (10 mg/kg). they provided color analog scale pain scores at baseline and at 20, 40, and 60 minutes after medication administration. the primary outcome measured was the difference in changes in pain score at 40 minutes, compared against a previously described minimal clinically significant change in pain score of 2 cm. additional outcomes included need for rescue medication and adverse effects.

Eligibility criteria:
inclusion criteria: * 5 to 18 years of age * spoke english as a primary language * complained of an extremity injury with tenderness to palpation from the clavicle or femoral neck to the distal phalanges * scored 5 or greater on a 10-point ordinal or varni-ryan pain scale administered at triage exclusion criteria: * allergy or prior adverse reaction to acetaminophen, codeine or ibuprofen; * administration of any analgesic within 6 hours of presentation; * significant deformity or vascular insufficiency of the extremity requiring immediate treatment as determined by the treating physician; * inability to use the study pain instrument; * any laceration near the suspected injury; * chronic hepatic or renal disease; * pregnancy in the third trimester; * concurrent use of contraindicated medications such as monoamine oxidase inhibitors; or * use of central nervous system depressants such as ethanol, benzodiazepines, barbiturates, antidepressants, or recreational drugs

Keywords: child pain analgesics
omega 3 supplementation in children with non alcoholic fatty liver

Conditions: Fatty Liver

Summary: this is a prospective, interventional, open-label, randomized study on the efficacy of omega 3 fatty acids supplementation in egyptian children with non-alcoholic fatty liver disease who had been selected from nutrition and outpatient clinic at pediatric hospital, ain shams university


Eligibility criteria:
inclusion criteria: children between 5 - 16 years old with diffusely hyper echogenic liver at ultrasonography were included in the study. exclusion criteria: * patients with secondary causes of steatosis including total parenteral nutrition, drugs causing fatty liver disease for example steroids, hepatitis a, b, c, cytomegalovirus, epstein-barr virus infections, autoimmune liver disease, metabolic liver diseases, wilson's disease, and alpha-1-antitrypsin deficiency. * patients currently taking fish oil supplements. * patients with systemic illness such as cardiac and kidney diseases.
effectiveness of a 24 hour phone line on the rate of suicide attempts in borderline patients

Conditions: Borderline Personality Disorder

Summary: this randomized multicentric clinical trial assesses the effectiveness of 24 hour phone line on the rate of suicide attempts and self-injurious behaviors in borderline patients.

borderline personality disorder is very frequent among psychiatric populations, and chronic suicidality is a major problem in clinical practice with borderline patients. in a lot of countries, suicide prevention centers are available, but most of these centers are not supervised by professionals of mental health, and none is specifically oriented to the borderline population. the main goal of this study is to assess the effectiveness of a 24 hour crisis phone line on the rate of suicide attempts in a clinical population of borderline patients (the effectiveness of this phone line access on the rate of self-injurious behaviours will also be studied). in this multicentric controlled trial, 600 borderline patients (men or women, in or out-patients, between 18 and 40 years-old) are randomized in two arms : * one with treatment as usual * one with treatment as usual, plus one year of access to a 24 hour crisis phone line (with a team of psychiatrists specialized in borderline personality disorder). all patients are assessed with standardized instruments (interviewers are blind to the patient's status), at entry (t1) and one year later (t2).

Eligibility criteria:
inclusion criteria: * 18 to 40 years old * in or out-patient in one of the recruiting center * men or women * with a borderline personality disorder * written informed consent exclusion criteria: * inferior to 18 or superior to 40 years old * schizophrenia * severe somatic disorder * participation refusal * participation to another interventional study

Keywords: borderline personality disorder suicide suicidality suicide attempt suicidal behavior self-injurious behavior self-harm behavior suicide prevention center telephone intervention
administrative workload in the intensive care unit

Conditions: Critical Illness

Summary: a prospective observational study in the intensive care unit and the medium care unit in a university hospital in amsterdam. recent studies show that administrative tasks occupy more than 30% of the workload. one-third of these administrative tasks is unrelated to care. the administrative workload of physicians and nurses will be observed and quantified using two different methods. the amount of time physicians and nurses are logged on into the patient data management system (pdms) will be measured and the time spent on different work tasks will be monitored with a work sampling method. two different patient data management systems will be compared.

in recent years, regulatory authorities request a growing number of protocols and checklists to improve healthcare. though the intention is to prevent medical mistakes and to improve patient care, these demands might result in an increased administrative workload for physicians and nurses. recent studies show that administrative tasks and documentation occupy more than thirty percent of the workload of physicians, of which one-third is unrelated to care. this time spent on administration could lower the amount of time spent with the patient and the patient's family. in the intensive care unit and the medium care unit, most of the administrative tasks are executed within the patient data management system. the way an electronic patient data management system is set up could impact the administrative workload for physicians and nurses. a prospective observational study at the department of intensive and medium care of the university medical centre will be performed with the aim to quantify the time spent on direct patient care versus administrative work. two different patient data management systems will be compared at different points in time. the nursing activity score and other patient characteristics will be registered for all the admitted patients during the two study periods. the administrative workload of physicians and nurses will be measured before and after the implementation of a new patient data management system, using the following methods: * login time in the electronic patient data management system during fourteen consecutive days in the intensive care unit and the medium care unit * timing of activities of physicians and nurses with a work sampling method during five consecutive day shifts in the intensive care unit

Eligibility criteria:
inclusion criteria: * admission to the intensive care unit during one of the two study periods exclusion criteria: * not applicable

Keywords: administrative workload patient data management system intensive care unit work sampling method nursing activity score
a study to evaluate methodologies for measuring swelling of the leg and ankle (mk-0000-106)(completed)

Conditions: Hypertension

Summary: this study will evaluate methodologies for measuring pedal edema associated with calcium channel blockers in middle-aged and elderly subjects and patients with hypertension.


Eligibility criteria:
inclusion criteria: * patient does not have hypertension or has stage i or ii hypertension and is taking \< 3 anti-hypertension medications * patient is willing to discontinue all anti-hypertensive medications during study * patient is willing to refrain from drinking alcohol for 24 hours prior to each study visit and is willing to limit intake at other times during the study to 2 drinks per day * patient agrees to avoid caffeine for 24 hours prior to each study visit. at other times during study, daily caffeine intake should not exceed 4 cups of coffee (or equivalent) * patient will avoid strenuous physical activity during study * patient is a nonsmoker or has not smoked for the last 3 months exclusion criteria: * patient has metal implants in the leg or artificial limbs * patient has had a lower limb amputation, malformation, alterations in leg muscles, or a history of musculoskeletal disease * patient has used oral contraceptive pills or hormone replacement therapy within 3 months of screening * patient has a history of stroke or seizures * patient has a history of cancer, except that which was treated at least 10 years prior to screening and shows no evidence of recurrence
to evaluate the role of intravitreal aflibercept injection (2.0 mg) in the management of previously treated patients with exudative amd

Conditions: AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)

Summary: this is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for amd and have persistent or recurrent fluid despite monthly intravitreal anti-vegf therapy.


Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study * age \> 50 years * choroidal neovascularization secondary to amd * best corrected visual acuity in the study eye between 20/25 to 20/400 using an etdrs chart * documentation of presence of subretinal fluid and/or cystoid macular edema on sd-oct following at least four anti-vegf treatments within six months before enrollment and a maximum of 5 years of years of treatment for neovascular amd * documentation of presence of subretinal fluid and/or cystoid macular edema less than 30 days since last treatment exclusion criteria: * pregnancy (positive pregnancy test) or lactation * premenopausal women not using adequate contraception. the following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an iud, or contraceptive hormone implant or patch. * participation in another simultaneous medical investigation or trial * prior treatment with anti-vegf therapy in the study eye within 30 days of bsl * prior treatment with pdt within the past 3 months or more than 4 prior pdt treatments. * presence of significant subfoveal fibrosis or atrophy. * prior treatment with intravitreal aflibercept injection * prior treatment with triamcinolone in the study eye within 6 months of bsl. * prior treatment with dexamethasone in the study eye within 30 days prior to bsl * intraocular surgery (including cataract surgery) in the study eye within 2 months preceding bsl * history of vitrectomy surgery, submacular surgery, or other surgical intervention for amd in the study eye * active intraocular inflammation (grade trace or above) in the study eye * current vitreous hemorrhage in the study eye * history of rhegmatogenous retinal detachment or macular hole (stage 3 or 4) in the study eye * ocular or periocular infection * active severe intraocular inflammation * uncontrolled glaucoma in the study eye (defined as iop ≥ 30 mmhg despite treatment with anti-glaucoma medication) * history of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment. * history of allergy to fluorescein, icg or iodine, not amenable to treatment * known hypersensitivity to aflibercept or to any of the excipients